SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
FDA signage at its headquarters in Maryland
Regulatory
FDA Moves to Cut Back on Testing Antibodies on Primates
For certain monospecific antibodies, three-month toxicology studies plus other supportive evidence will suffice, eliminating the need for six-month testing.
December 3, 2025
 · 
2 min read
 · 
Tristan Manalac
Podcast
Prasad’s Leaked FDA Memo, Alzheimer’s Ups and Downs, Next-Gen Obesity Drugs
Experts unpack the implications of CBER Director Vinay Prasad’s claim that COVID vaccines have caused 10+ child deaths; the 2025 Clinical Trials on Alzheimer’s Disease conference continues following two disappointing readouts; and Novo Nordisk’s amycretin yields promising weight loss results.
December 3, 2025
 · 
1 min read
 · 
Heather McKenzie
Hand turns dice and changes the expression 'know the rules'. to 'follow the rules'.
Insights
New UK/EU Rules and AI Adoption Define CRO Priorities for 2026
With new UK clinical trial rules landing in 2026, the EU Biotech Act on the horizon and China and Australia gaining ground, CROs are zeroing in on study timelines, AI/ML and data privacy as the industry’s next pressure points.
December 3, 2025
 · 
4 min read
 · 
Jennifer C. Smith-Parker
Tariff Trade Disaster and drowning with economic tariffs and market crash anxiety with government taxation or duties imposed on imports and exports on imported or exported goods as Protectionism.
Opinion
Even Early Stage Biotechs Can’t Ignore Tariffs
Early decisions about manufacturing and supply chains could prove costly as a company reaches the commercial stage.
December 3, 2025
 · 
4 min read
 · 
Josh Medow
investment compound interest growth, increase in the value of money savings, additional value from capital or investment, business woman investment makes a growth graph using gold money coins
Business
Top 5 VC Raises by Women-Founded Biopharmas
Venture capital flow to women-founded companies has stabilized in the post-pandemic environment. BioSpace looks back at five companies that have nabbed the most over the past two decades.
December 3, 2025
 · 
6 min read
 · 
Annalee Armstrong
Aircrafts landing and taking off at airport by night - vector illustration
Venture capital
Lilly, Novo GLP-1 Pricing Plans Clear Runway for Future Competitors
While the TrumpRx deals only cover Lilly and Novo for now, the agreements are good for any cardiometabolic biotechs waiting in the wings, according to a new 2026 preview report from PitchBook.
December 3, 2025
 · 
2 min read
 · 
Annalee Armstrong
Richard Pazdur
FDA
Pazdur To Retire Weeks After Taking On Coveted FDA Role
Newly appointed Center for Drug Evaluation and Research director Richard Pazdur has filed retirement papers with the agency—three weeks after accepting the role—amid clashes with Commissioner Marty Makary over certain FDA programs.
December 2, 2025
 · 
3 min read
 · 
Heather McKenzie
Direction uncertainty with a landscape of confused tangled roads and highways and a group of traffic signs competing for influence as a symbol of the challenges of planning a strategy for success.
Regulatory
Experts Decry Prasad Memo’s Lack of Transparency as Vaccine Stocks Dip
With no evidence to support the claim that 10 children died due to COVID-19 vaccines, experts unpack the impact of CBER chief Vinay Prasad’s leaked vaccine memo.
December 2, 2025
 · 
4 min read
 · 
Dan Samorodnitsky
Axial view of the brain showing a glioblastoma in the left frontal lobe with central necrosis, peripheral infiltration, and early midline shift.
Brain cancer
Imvax Heads to FDA With 6-Month Survival Gain in Glioblastoma, Despite Endpoint Miss
While Imvax’s autologous immunotherapy IGV-001 missed the primary endpoint of progression-free survival in a Phase IIb trial, the company will request a meeting with the FDA to discuss next steps for “synergistic” treatment.
December 2, 2025
 · 
2 min read
 · 
Dan Samorodnitsky
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS